Merck’s New Drug Application for an Investigational Intravenous (IV) Formulation of NOXAFIL® (posaconazole) Receives FDA Priority Review
Dateline City:
WHITEHOUSE STATION, N.J.
Marketing Authorization Application also Filed with the European Medicines Agency
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that its New Drug Application for an investigational
intravenous (IV) solution formulation of the company's antifungal agent,
NOXAFIL® (posaconazole), has been accepted for priority
review by the U.S. Food and Drug Administration (FDA).
Language:
English
Contact:
MerckMedia Contacts:Pam Eisele, 908-423-5042orRobert Consalvo, 908-423-6595orInvestor Contacts:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news